Amredobresib
Amredobresib (BI894999) is an orally active BET inhibitor. Amredobresib inhibits the binding of BRD4-BD1 and BRD4-BD2 bromodomains to acetylated histones with IC50 values of 5 nM and 41 nM, respectively. Amredobresib exhibits anticancer activity against acute myeloid leukemia (AML) and NUT cancer[1][2][3][4][5].
Product Specifications
CAS Number
1610044-98-8
Product Name Alternative
BI894999
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/amredobresib.html
Purity
98.97
Solubility
DMSO : 1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CNC1=NC(C2=NC3=C(N2CC4=CC=CC=C4)C=C(N5CCN(CC5)C)C=C3)=CN6C(C)=NN=C16
Molecular Formula
C26H29N9
Molecular Weight
467.57
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![MAPK14 Mouse Monoclonal Antibody [9-B9]](https://cdn.genprice.uk/products/992/68dd1c90061270361ea82a9d/imageurl/em40307.webp)
